TABLE OF CONTENTS
1 INTRODUCTION 10
1.1 OBJECTIVES OF THE STUDY 10
1.2 MARKET DEFINITION 10
1.3 OVERVIEW OF CHINA FENO TESTING MARKET 10
1.4 LIMITATIONS 11
1.5 MARKETS COVERED 12
2 MARKET SEGMENTATION 13
2.1 MARKETS COVERED 13
2.2 GEOGRAPHICAL SCOPE 14
2.3 YEARS CONSIDERED FOR THE STUDY 14
2.4 CURRENCY AND PRICING 14
2.5 DBMR TRIPOD DATA VALIDATION MODEL 15
2.6 MULTIVARIATE MODELLING 18
2.7 LIFELINE CURVE, BY TYPE 19
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
2.9 DBMR MARKET POSITION GRID 21
2.10 SECONDARY SOURCES 23
2.11 ASSUMPTIONS 23
3 EXECUTIVE SUMMARY 24
4 PREMIUM INSIGHTS 26
5 COVID-19 PANDEMIC IMPACT ANALYSIS:- 27
5.1 SUPPLY CHAIN IMPACT ANALYSIS:- 27
5.2 DEMAND IMPACT ANALYSIS:- 28
5.3 PRICE IMPACT ANALYSIS:- 28
6 MARKET OVERVIEW 29
6.1 DRIVERS 31
6.1.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES 31
6.1.2 HIGH ADOPTION OF FENO MONITORING IN REDUCING ASTHMA EXACERBATION 32
6.1.3 TECHNOLOGICAL ADVANCEMENTS IN FENO TESTING 33
6.1.4 INCREASING AWARENESS REGARDING THE BENEFITS OF FENO TESTING 34
6.2 RESTRAINTS 35
6.2.1 HIGH COST OF FENO TESTING PRODUCTS 35
6.2.2 INADEQUATE REIMBURSEMENT SCENARIO 35
?
6.3 OPPORTUNITIES 36
6.3.1 RISING GOVERNMENT INITIATIVES AND PUBLIC PRIVATE PARTNERSHIP 36
6.3.2 INCREASING DIAGNOSTIC RATE ESPECIALLY ALLERGIC DIAGNOSTIC 37
6.4 CHALLENGE 38
6.4.1 STRINGENT LEGAL FRAMEWORK 38
7 CHINA FENO TESTING MARKET, BY TYPE 40
7.1 OVERVIEW 41
7.2 NITRIC OXIDE HANDHELD MONITOR 44
7.3 NITRIC OXIDE STANDALONE MONITOR 44
7.4 OTHERS 44
8 CHINA FENO TESTING MARKET, BY INDICATION 45
8.1 OVERVIEW 46
8.2 EOSINOPHILIC AIRWAY INFLAMMATION 49
8.3 ATOPIC ASTHMA 49
8.4 CHRONIC RESPIRATORY SYMPTOMS 49
8.5 COPD WITH MIXED INFLAMMATORY PHENOTYPE 50
8.6 EOSINOPHILIC BRONCHITIS 50
8.7 PULMONARY ARTERIAL HYPERTENSION 50
8.8 CORTICOSTEROID RESPONSIVENESS 50
8.9 CYSTIC FIBROSIS 51
8.10 OTHERS 51
9 CHINA FENO TESTING MARKET, BY END USER 52
9.1 OVERVIEW 53
9.2 HOSPITALS 56
9.3 DIAGNOSTIC CENTERS 56
9.4 CLINICS 56
9.5 AMBULATORY SURGICAL CENTERS 56
9.6 HOMECARE SETTING 56
9.7 OTHERS 57
10 CHINA FENO TESTING MARKET, BY DISTRIBUTION CHANNEL 58
10.1 OVERVIEW 59
10.2 DIRECT TENDER 62
10.3 RETAIL SALES 62
10.4 ONLINE SALES 62
11 CHINA FENO TESTING MARKET, COMPANY LANDSCAPE 63
?
12 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS 64
12.1 SWOT ANALYSIS 64
12.1.1 STRENGTH: - INCREASING FOCUSED ON RESPIRATORY DISEASE 64
12.1.2 WEAKNESS: - EXTERNAL DEPENDENCE 64
12.1.3 OPPORTUNITY: - STRATEGIC BUSINESS INITIATIVES 65
12.1.4 THREAT: - FOREIGN EXCHANGE VOLATILITY 65
12.2 DATA BRIDGE MARKET RESEARCH ANALYSIS 66
13 COMPANY PROFILE 67
13.1 CIRCASSIA 67
13.1.1 COMPANY SNAPSHOT 67
13.1.2 REVENUE ANALYSIS 68
13.1.3 PRODUCT PORTFOLIO 68
13.1.4 RECENT DEVELOPMENT 68
13.2 SUNVOU 69
13.2.1 COMPANY SNAPSHOT 69
13.2.2 PRODUCT PORTFOLIO 69
13.2.3 RECENT DEVELOPMENT 69
13.3 SPIROSURE, INC. 70
13.3.1 COMPANY SNAPSHOT 70
13.3.2 PRODUCT PORTFOLIO 70
13.3.3 RECENT DEVELOPMENT 70
13.4 BEDFONT SCIENTIFIC LTD. 71
13.4.1 COMPANY SNAPSHOT 71
13.4.2 PRODUCT PORTFOLIO 71
13.4.3 RECENT DEVELOPMENT 71
13.5 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 72
13.5.1 COMPANY SNAPSHOT 72
13.5.2 REVENUE ANALYSIS 72
13.5.3 PRODUCT PORTFOLIO 73
13.5.4 RECENT DEVELOPMENT 73
13.6 ECO MEDICS AG 74
13.6.1 COMPANY SNAPSHOT 74
13.6.2 PRODUCT PORTFOLIO 74
13.6.3 RECENT DEVELOPMENT 74
13.7 GUANGZHOU RUIPU MEDICAL TECHNOLOGY CO., LTD. 75
13.7.1 COMPANY SNAPSHOT 75
13.7.2 PRODUCT PORTFOLIO 75
13.7.3 RECENT DEVELOPMENT 75
?
13.8 MEDISOFT GROUP 76
13.8.1 COMPANY SNAPSHOT 76
13.8.2 PRODUCT PORTFOLIO 76
13.8.3 RECENT DEVELOPMENT 76
14 CONCLUSION 77
15 QUESTIONNAIRE 78
16 RELATED REPORTS 80